Current Report Filing (8-k)
September 13 2018 - 4:17PM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of the
Securities
Exchange Act of 1934
Date
of Report (Date of earliest event reported)
September
13, 2018 (September 12, 2018)
HEMISPHERX
BIOPHARMA, INC.
(Exact
name of registrant as specified in its charter)
Delaware
|
|
001
- 27072
|
|
52-0845822
|
(state
or other jurisdiction
|
|
(Commission
|
|
(I.R.S.
Employer
|
of
incorporation)
|
|
File
Number)
|
|
Identification
No.)
|
2117
SW Highway 484, Ocala FL
|
|
34474
|
(Address
of principal executive offices)
|
|
(Zip
Code)
|
Registrant’s
telephone number, including area code:
(407) 839-0095
2117
SW Highway 484, Ocala FL 34473
(Former
name or former address, if changed since last report)
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions (see General Instruction A.2. below):
[ ]
|
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
|
[ ]
|
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
|
[ ]
|
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
|
[ ]
|
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Indicate
by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act
of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company
[ ]
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for
complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
[ ]
Item
5.07 Submission of Matters to a Vote of Security Holders
The
Company’s Annual Meeting of Stockholders for 2018 was held on September 12, 2016. The requisite quorum for the meeting of
40.0% was present. At the meeting, stockholders voted as follows:
Election
of Directors
:
Nominees
|
|
For
|
|
|
Withheld
|
|
|
Broker Non-Votes
|
|
Thomas K. Equels
|
|
|
6,785,002
|
|
|
|
438,414
|
|
|
|
20,251,473
|
|
William M. Mitchell
|
|
|
6,580,686
|
|
|
|
642,730
|
|
|
|
20,251,473
|
|
Stewart L. Appelrouth
|
|
|
6,604,535
|
|
|
|
618,881
|
|
|
|
20,251,473
|
|
Ratification
of the selection of Morrison, Brown, Argiz & Farra, LLC as our independent accountants
:
For:
23,397,400
|
|
Against:
1,088,279
|
|
Abstain:
2,989,210
|
Advisory,
non-binding, vote on approval of the compensation of the Company’s Named Executive Officers
:
For:
5,422,897
|
|
Against:
1,325,480
|
|
Abstain:
475,039
|
The
following votes were cast with regard to approval the Hemispherx 2018 Equity Incentive Plan:
For:
4,807,712
|
|
Against:
1,944,762
|
|
Abstain:
470,942
|
The
following votes were cast with regard to approval of the Company’s name change:
For:
20,324,225
|
|
Against:
3,974,825
|
|
Abstain:
3,175,839
|
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf
by the undersigned hereunto duly authorized.
HEMISPHERX
BIOPHARMA, INC.
|
|
|
|
September
13, 2018
|
By:
|
/s/
Thomas K. Equels
|
|
|
Thomas
K. Equels, CEO
|
Hemispherx Biopharma (AMEX:HEB)
Historical Stock Chart
From Mar 2024 to Apr 2024
Hemispherx Biopharma (AMEX:HEB)
Historical Stock Chart
From Apr 2023 to Apr 2024